IGM Biosciences, Inc.
IGMS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.20 | -0.44 | -0.07 |
| FCF Yield | -42.96% | -47.07% | -2.27% | -14.01% |
| EV / EBITDA | -1.95 | -1.42 | -2.82 | -5.57 |
| Quality | ||||
| ROIC | -88.68% | -68.31% | -47.45% | -59.69% |
| Gross Margin | -240.13% | -288.59% | -891.77% | 0.00% |
| Cash Conversion Ratio | 0.78 | 0.78 | 0.03 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 35.83% | – | – | – |
| Free Cash Flow Growth | 22.37% | -1,174.13% | 88.33% | -62.23% |
| Safety | ||||
| Net Debt / EBITDA | -0.09 | 0.28 | 0.36 | 0.66 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 69.62 | -58.47 | -86.48 | -263.87 |